Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:IKTNASDAQ:KRRONASDAQ:MOLNNASDAQ:VRCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIKTInhibikase Therapeutics$2.20+4.3%$2.17$1.12▼$4.20$163.55M1.02230,784 shs136,608 shsKRROKorro Bio$17.47-3.4%$19.31$11.13▼$98.00$164.03M2.3195,478 shs109,246 shsMOLNMolecular Partners$4.08-2.9%$4.19$3.51▼$12.70$164.73M1.1620,917 shs82,348 shsVRCAVerrica Pharmaceuticals$0.46-5.1%$0.55$0.38▼$11.41$49.01M1.68584,549 shs231,326 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIKTInhibikase Therapeutics+4.27%+16.40%-3.93%-20.29%+28.65%KRROKorro Bio-3.43%+28.08%+0.17%-51.62%-72.24%MOLNMolecular Partners+0.62%+8.22%-4.47%-23.31%+5.15%VRCAVerrica Pharmaceuticals-5.11%-0.28%+7.18%-36.02%-93.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIKTInhibikase Therapeutics0.9643 of 5 stars3.30.00.00.00.00.00.6KRROKorro Bio1.5753 of 5 stars3.60.00.00.03.20.00.6MOLNMolecular Partners2.4348 of 5 stars3.83.00.00.03.00.00.6VRCAVerrica Pharmaceuticals4.2935 of 5 stars3.12.00.04.72.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIKTInhibikase Therapeutics 2.50Moderate Buy$6.50195.45% UpsideKRROKorro Bio 3.14Buy$120.43589.34% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00194.12% UpsideVRCAVerrica Pharmaceuticals 2.20Hold$9.501,946.97% UpsideCurrent Analyst Ratings BreakdownLatest VRCA, MOLN, KRRO, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.004/9/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.003/19/2025KRROKorro BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$105.00 ➝ $95.003/12/2025VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.002/12/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIKTInhibikase Therapeutics$260K629.05N/AN/A$1.78 per share1.24KRROKorro Bio$2.27M72.23N/AN/A$21.19 per share0.82MOLNMolecular Partners$4.97M33.14N/AN/A$5.41 per share0.75VRCAVerrica Pharmaceuticals$7.57M5.67N/AN/A$0.47 per share0.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AKRROKorro Bio-$81.17M-$9.39N/AN/AN/AN/A-50.25%-38.48%5/13/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.81N/AN/AN/A-1,043.01%-39.31%-35.46%5/15/2025 (Estimated)VRCAVerrica Pharmaceuticals-$67M-$1.54N/AN/AN/A-625.06%-591.84%-141.63%5/12/2025 (Estimated)Latest VRCA, MOLN, KRRO, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KRROKorro Bio-$2.60N/AN/AN/A$0.13 millionN/A5/12/2025Q1 2025VRCAVerrica Pharmaceuticals-$0.10N/AN/AN/A$2.53 millionN/A3/18/2025Q4 2024KRROKorro Bio-$2.33-$2.26+$0.07-$2.26N/A$2.27 million3/11/2025Q4 2024VRCAVerrica Pharmaceuticals-$0.25-$0.24+$0.01-$0.24$1.30 million$0.34 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIKTInhibikase TherapeuticsN/A0.850.85KRROKorro BioN/A11.2311.23MOLNMolecular PartnersN/A14.3314.33VRCAVerrica PharmaceuticalsN/A1.341.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIKTInhibikase Therapeutics3.81%KRROKorro Bio13.18%MOLNMolecular Partners26.55%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipIKTInhibikase Therapeutics4.59%KRROKorro Bio5.40%MOLNMolecular Partners5.93%VRCAVerrica Pharmaceuticals42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableKRROKorro Bio709.39 million8.86 millionNo DataMOLNMolecular Partners18040.38 million37.97 millionNot OptionableVRCAVerrica Pharmaceuticals4092.46 million26.18 millionOptionableVRCA, MOLN, KRRO, and IKT HeadlinesRecent News About These CompaniesVerrica Pharmaceuticals (NASDAQ:VRCA) Earns Hold Rating from Needham & Company LLCApril 11, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VRCA FY2028 EarningsApril 11, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)April 10, 2025 | marketbeat.comWhy Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 5.94%April 10, 2025 | aaii.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comVerrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1April 8, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025April 7, 2025 | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)April 5, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of DirectorsApril 4, 2025 | msn.comVerrica Pharmaceuticals Appoints Dr. Corcoran as DirectorApril 2, 2025 | tipranks.comVerrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of DirectorsApril 2, 2025 | globenewswire.comVerrica Pharmaceuticals to Present at Needham Healthcare ConferenceApril 2, 2025 | msn.comHere's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock NowApril 1, 2025 | zacks.comHarmony, Lungpacer, Verrica and Arbutus make C-suite hiresApril 1, 2025 | bizjournals.comVerrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comVerrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical OfficerMarch 28, 2025 | msn.comVerrica Pharmaceuticals appoints Rosenberg as CMOMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical OfficerMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.March 26, 2025 | globenewswire.comVerrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline ProgressMarch 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRCA, MOLN, KRRO, and IKT Company DescriptionsInhibikase Therapeutics NYSE:IKT$2.20 +0.09 (+4.27%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$2.20 0.00 (0.00%) As of 04/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Korro Bio NASDAQ:KRRO$17.47 -0.62 (-3.43%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$17.93 +0.46 (+2.63%) As of 04/28/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Molecular Partners NASDAQ:MOLN$4.08 -0.12 (-2.86%) Closing price 04/28/2025 03:53 PM EasternExtended Trading$4.02 -0.06 (-1.47%) As of 04/28/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Verrica Pharmaceuticals NASDAQ:VRCA$0.46 -0.03 (-5.11%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$0.46 0.00 (-0.67%) As of 04/28/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
